Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging proof-of-concept study of Osteogrow-C in tibial non-union
2021-004034-11Phase 2Terminated
- Sponsor
- Genera Research Ltd.
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Osteogrow-C in Tibial non-union (2 arms), sponsored by Genera Research Ltd. Primary endpoint: Clinical success at 9 months after surgery. Started Apr 2022; status: terminated.
02
Drugs
Osteogrow-C
03
Conditions
Tibial non-union
Beyond the preview
Go deeper on 2021-004034-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004034-11.